Cancer
Conditions
Keywords
CLL, Leukemia, Chronic Lymphocytic, Hsp90, BTK, Ibrutinib
Brief summary
SNX-5422 is a prodrug of SNX-2112, a potent, highly selective, small molecule inhibitor of the molecular chaperone heat shock protein 90 (HSP90). Hsp90 inhibitors may overcome ibrutinib resistance in Mantle cell lymphomas and this study will investigate whether the addition of SNX-5422 to an established dose of ibrutinib will result in the removal of mutated BTK from blood mononuclear cells and/or prevents or delays disease progression of subjects with CLL
Detailed description
Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in adults and is not considered curable outside of allogeneic stem cell transplantation. BTK is a critical kinase in the B cell receptor signaling pathway. This pathway is amplified in CLL and results in amplification of proliferation and anti-apoptotic signals. By inhibiting BTK, ibrutinib eliminates the activation of these pro-survival pathways and microenvironment survival signals. While response to ibrutinib has been high with therapy well-tolerated overall, some patients have relapsed while others have been taken off therapy for toxicity or other reasons. Relapse in CLL can be mediated by at least two separate mechanisms. One is by mutations in BTK, which both decrease ibrutinib's affinity for BTK, and also changes the binding from irreversible to reversible. This is a proof of concept study to investigate whether the addition of SNX-5422 to an established dose of ibrutinib will reduce mutated BTK from CLL cells and/or prevents or delays disease progression of subjects with CLL. This is an open-label study of SNX-5422 combined with ibrutinib. In each 28 day cycle, SNX-5422 will be dosed in the morning once every other day for 21 days, followed by a 7-day drug-free period. Subjects will continue to receive daily oral ibrutinib at their established dose level in the afternoon every day for 28 days. cycle
Interventions
SNX-5422 capsule(s) dosed every other day for 21 days out of a 28-day treatment cycle to a total dose of 56 mg/m2 SNX-5422. Subjects will self-administer daily oral ibrutinib in the afternoon at least 8 hours apart from SNX-5422 for 28 days of each cycle.
Sponsors
Esanex Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Males or non-pregnant, non-breastfeeding females 18 years-of-age or older * A diagnosis of CLL as defined by IWCLL 2008 criteria and currently on treatment with ibrutinib without evidence of disease progression. * No more than 4 prior lines of anti leukemia therapy (not including ibrutinib) * Presence of mutated BTK in ≥ 4% of peripheral blood or bone marrow CLL cells, or ≥1% and rising on two separate measurements obtained at least 28 days apart. * Life expectancy of at least 9 months * Karnofsky performance score 70 * Adequate baseline laboratory assessments * Signed informed consent form * Recovered from toxicities of previous anticancer therapy to CTCAE Grade ≤ 1 with the exception of alopecia * Subjects with reproductive capability must agree to practice adequate contraception methods.
Exclusion criteria
* Subjects experiencing toxicity with ibrutinib * Prior treatment with any Hsp90 inhibitor. * Major surgery or significant traumatic injury within 4 weeks of starting study treatment. * Conventional chemotherapy or radiation within 4 weeks. * The need for treatment with medications with clinically-relevant metabolism by the cytochrome P450 (CYP) 3A4 isoenzyme within 3 hours before or after administration of SNX-5422 * Screening ECG QTc interval 470 msec for females, 450 msec for males. * At increased risk for developing prolonged QT interval unless corrected to within normal limits prior to first dose of SNX-5422 * Patients with chronic diarrhea or with Grade 2 or greater diarrhea despite appropriate medical management. * Gastrointestinal diseases or conditions that could affect drug absorption * Gastrointestinal diseases that could alter the assessment of safety, including irritable bowel syndrome, ulcerative colitis, Crohn's disease, or hemorrhagic coloproctitis. * History of documented adrenal dysfunction not due to malignancy. * History of chronic liver disease. * Active hepatitis A or B. * Current alcohol dependence or drug abuse. * Use of an investigational treatment (except for ibrutinib) from 30 days prior to the first dose * Glaucoma, retinitis pigmentosa, macular degeneration, or any retinal changes detected by ophthalmological examination that are considered clinically important by examiner. * Psychological or social reasons that would hinder or prevent compliance with the requirements of the protocol or compromise the informed consent process.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy of the combination of SNX-5422 and ibrutinib | Every 12 weeks up to 52 weeks | Change in percent of mutated BTK in CLL cells |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of subjects reporting adverse events | Day 28 of each 4 week cycle from randomization up to 52 weeks | Frequency and severity of adverse events |
| Time to disease progression | Up to 52 weeks | Elapsed time for each subject from randomization to relapse of disease up to 52 weeks |
| Clinical Laboratory testing | Day 28 of each 4 week cycle from randomization up to 52 weeks | Absolute values and changes from baseline for each subject using standard clinical chemistry, hematology and urinalysis parameters |
| Electrocardiogram | Pre-dose on Day 1 of each 4 week cycle from randomization up to 52 weeks | Digital 12-lead ECG using standard recording methods at trough drug levels. All ECG recordings will be analyzed for PR, RR, QT intervals, and for morphology. |
Countries
United States
Outcome results
None listed